Axsome Therapeutics在阿尔茨海默病与脑健康意识月期间倡导脑健康-动脉网

Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month

Axsome Therapeutics 等信源发布 2025-06-20 19:31



可切换为仅中文







Download PDF

下载PDF

NEW YORK

纽约

，

June 20, 2025

2025年6月20日

(GLOBE NEWSWIRE) --

（环球新闻网）——

Axsome Therapeutics, Inc.

(NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today is joining with the Alzheimer’s disease advocacy community to raise awareness of the growing impact of Alzheimer’s disease in

(NASDAQ: AXSM)是一家引领中枢神经系统（CNS）疾病治疗新时代的生物制药公司，今天将与阿尔茨海默病倡导社区联合起来，提高人们对阿尔茨海默病日益增长的影响的认识。

the United States

美国

and the importance of brain health during this year’s Alzheimer’s & Brain Awareness Month.

今年的阿尔茨海默病与脑健康意识月期间，大脑健康的重要性。

“Alzheimer’s & Brain Awareness Month offers the perfect opportunity for all Americans to take charge of their brain health,” said

“阿尔茨海默病与大脑意识月为所有美国人提供了一个掌控自己大脑健康的绝佳机会，”

Sarah Fried

萨拉·弗里德

, Vice President of Corporate Initiatives at the

公司计划副总裁

Alzheimer's Association

阿尔茨海默病协会

. “For the first time ever there are now more than 7 million Americans living with Alzheimer’s disease, but progress is being made, both with the development of new treatment options and in understanding overall brain health. It is estimated that as many as 45% of dementia cases may be attributable to modifiable risk factors.

“有史以来首次，现在有超过700万美国人患有阿尔茨海默病，但正在取得进展，不仅在开发新的治疗方案方面，也在于对整体大脑健康的理解。据估计，多达45%的痴呆病例可能归因于可改变的风险因素。”

Research shows that adopting healthy behaviors — like getting exercise and good quality sleep — can improve your brain health and reduce the risk of cognitive decline and can be an important part of a comprehensive health program.“.

研究表明，采用健康的行为——比如锻炼和获得高质量的睡眠——可以改善大脑健康，降低认知能力下降的风险，并且可以成为综合健康计划的重要部分。

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, and behavioral and psychological symptoms including agitation. AD is the most common form of dementia and afflicts an estimated 7.2 million individuals in

阿尔茨海默病（AD）是一种进行性神经退行性疾病，其特征是认知能力下降以及包括躁动在内的行为和心理症状。AD 是最常见的痴呆形式，据估计已影响 720 万人。

the United States

美国

, a number that is anticipated to increase to approximately 14 million by 2060.

，预计到2060年这一数字将增加到约1400万。

An additional nearly 12 million people serve as their caregivers.

此外，还有近1200万人担任他们的护理人员。

The long duration of the condition exacerbates the impact and burden on individuals and public health. According to the most recent Global Burden of Disease classification system, Alzheimer’s disease rose from the 12th most burdensome disease or injury in

该病程较长，加重了对个人和公共卫生的影响与负担。根据最新的全球疾病负担分类系统，阿尔茨海默病从第12位最沉重的疾病或伤害上升为

the United States

美国

in 1990 to the sixth in 2016 in terms of disability-adjusted life years (DALYs).

在1990年到2016年期间，按残疾调整生命年（DALYs）计算，排名从第十五位上升到第六位。

During Alzheimer’s & Brain Awareness Month, Axsome is working with advocacy and patient communities to raise awareness and share resources, in addition to participating at scientific and medical conferences throughout the year.

在阿尔茨海默病与脑意识月期间，Axsome 除了全年参与科学和医学会议外，还正在与倡导者和患者社区合作，提高意识并分享资源。

To learn more about Alzheimer’s disease advocacy organizations and some of the resources they provide supporting individuals with Alzheimer’s and their family members or caregivers, please visit the following websites:

要了解更多关于阿尔茨海默病宣传组织及其提供的支持阿尔茨海默病患者和他们的家人或护理人员的资源，请访问以下网站：

Alzheimer’s Association (

阿尔茨海默病协会 (

https://www.alz.org/

）。

The Alzheimer’s Association leads the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support.

阿尔茨海默病协会致力于通过加速全球研究、推动风险降低和早期检测以及最大化护理和支持质量，来终结阿尔茨海默病及其他所有痴呆症。

Alzheimer’s

阿尔茨海默病

Foundation of America

美国基金会

(

https://alzfdn.org/

）。

The Alzheimer’s

阿尔茨海默病

Foundation of America

美国基础

(AFA) provides support, services and education to individuals, families and caregivers affected by Alzheimer’s disease and related dementias nationwide, and funds research for better treatment and a cure.

阿尔茨海默病协会（AFA）为全国受阿尔茨海默病及相关痴呆症影响的个人、家庭和护理人员提供支持、服务和教育，并资助用于更好治疗和治愈方法的研究。

Caregiver Action Network (

照顾者行动网络 (

https://www.caregiveraction.org/

）。

Caregiver Action Network (CAN) is the nation’s leading family caregiver organization working to improve the quality of life for the more than 90 million Americans who care for loved ones with chronic conditions, disabilities, or disease, as well as those supporting the living needs of older adults.

家庭护理行动网络（CAN）是全美领先的家庭护理者组织，致力于改善超过9000万美国人的生活质量。这些美国人照顾着患有慢性病、残疾或疾病的亲人，同时也为老年人的生活需求提供支持。

CaringKind (

https://www.caringkindnyc.org/

）。

CaringKind is New York City’s leading expert on Alzheimer’s and dementia caregiving. With over 40 years of experience, CaringKind works directly with its community partners to develop the information, tools and training to support individuals and families affected by dementia.

CaringKind 是纽约市在阿尔茨海默病和痴呆护理方面的领先专家。拥有超过 40 年的经验，CaringKind 直接与社区合作伙伴合作，开发信息、工具和培训，以支持受痴呆影响的个人和家庭。

Family Caregiver Alliance

家庭照顾者联盟

(

https://www.caregiver.org/

For more than 40 years,

超过40年的时间里，

Family Caregiver Alliance

家庭照顾者联盟

(FCA) has provided services to family caregivers of adults with physical and cognitive impairments, such as Parkinson’s, stroke, Alzheimer’s and other types of dementia.

家庭照顾者协会 (FCA) 为患有身体和认知障碍（如帕金森病、中风、阿尔茨海默病和其他类型的痴呆症）的成年人的家庭照顾者提供服务。

National Alliance for Caregiving

全国护理联盟

(

https://www.caregiving.org/

）。

The

这

National Alliance for Caregiving

全国护理联盟

is a non-profit coalition of national organizations who share a vision of a society that values, supports and empowers family caregivers to thrive at home, work and life. Its mission is to build partnerships in research, advocacy, and innovation to make life better for family caregivers.

是一个由全国性组织组成的非营利联盟，这些组织共同拥有一个愿景，即社会重视、支持并赋予家庭照顾者在家务、工作和生活中茁壮成长的能力。其使命是通过研究、倡导和创新建立合作关系，以改善家庭照顾者的生活质量。

About

关于

Axsome Therapeutics

is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes.

是一家引领中枢神经系统（CNS）疾病治疗新时代的生物制药公司。我们通过识别护理中的关键差距，开发具有新颖作用机制的差异化产品，从而实现科学突破，为患者带来有意义的治疗进展。

Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in .

我们行业领先的神经科学产品组合包括FDA批准的用于治疗重度抑郁症、与嗜睡症和阻塞性睡眠呼吸暂停相关的过度日间嗜睡以及偏头痛的疗法，并且还有多个针对广泛严重神经和精神疾病的晚期开发项目，这些疾病影响着超过1.5亿人。

the United States

美国

. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at

。我们共同致力于解决大脑的一些最大问题，以便患者及其亲人能够茁壮成长。欲了解更多信息，请访问我们的网站

www.axsome.com

and follow us on

关注我们

领英

and

和

。

Forward Looking Statements

前瞻性声明

Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.

本新闻稿中讨论的某些事项为“前瞻性陈述”。公司在某些情况下可能会使用“预测”、“相信”、“潜在”、“继续”、“估计”、“预期”、“计划”、“意图”、“可能”、“能够”、“也许”、“将”、“应该”等词语来表达未来事件或结果的不确定性，以此识别这些前瞻性陈述。

In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI.

特别是，公司关于趋势和潜在未来结果的声明属于此类前瞻性陈述的例子。前瞻性声明包含风险和不确定性，包括但不限于公司SUNOSI的商业成功。

, AUVELITY

，AUVELITY

, and SYMBRAVO

，以及SYMBRAVO

products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain .

产品以及公司为solriamfetol和/或AXS-05获得任何额外适应症的努力的成功；公司维持和扩大支付方覆盖的能力；公司正在进行的临床试验及预计进行的临床试验的成功、时间安排和成本，针对公司当前候选产品的声明，包括关于试验启动时间、入组速度和完成情况（包括公司完全资助其已披露临床试验的能力，该能力假设公司目前预测的收入或支出没有重大变化）、无效性分析和中期结果的接收，这些结果不一定反映公司正在进行的临床试验的最终结果，和/或数据读出结果，以及支持公司当前任何候选产品新药申请（“NDA”）所需的研究数量或类型或结果性质；公司为继续推进其候选产品而资助额外临床试验的能力；公司获取和维持的时间和能力。

U.S. Food and Drug Administration

美国食品药品监督管理局

(“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control.

（“FDA”）或其他监管机构对公司产品候选物的批准或其他行动，包括有关任何新药申请（NDA）提交时间的声明；公司成功捍卫其知识产权或以公司可接受的成本获得必要许可的能力（如果可以的话）；公司成功解决任何知识产权诉讼的能力，即使这些争议得以解决，相关联邦机构是否会批准此类和解；公司研发计划和合作的成功实施；公司许可协议的成功；市场对公司产品及产品候选物的接受度（如获批准）；公司预期的资本需求，包括商业化SUNOSI、AUVELITY和SYMBRAVO所需的资本金额以及公司其他产品候选物商业化推出（如获批准）所需的资本金额，及其对公司预期现金跑道的潜在影响；公司将销售转化为确认收入并保持有利的总销售额与净销售额比率的能力；由于国内政治气候、地缘政治冲突或全球疫情引发或相关的意外情况或其他对正常业务运营的干扰，以及其他因素，包括一般经济状况和不受公司控制的监管发展。

The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking sta.

本文讨论的因素可能导致实际结果和发展与这些陈述所表达或暗示的有重大差异。前瞻性声明仅在本新闻稿发布之日作出，公司不承担公开更新此类前瞻性声明的义务。

Investors:

投资者：

Mark Jacobson

马克·雅各布森

Chief Operating Officer

首席运营官

(212) 332-3243

mjacobson@axsome.com

Media:

媒体：

Darren Opland